HUTCHMED (China)

HCM · HONG

$14.36+$0.08 (+0.56%)TodayMarket closed ·
Prev close $14.28

About HCM

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Employees
1,796
Headquarters
Hong Kong
Listed
May 19, 2006
Sector
Health Care
Industry
Pharmaceuticals

Leadership

HUTCHMED (China) executives
NameTitleSince
Dan Eldar——
Weiguo Su—2017
Chig Fung Cheng—2011
Karen Atkin——
Hong Chen——
Ming Shi——
Zhenping Wu——
Kin Hung Lee—2023
Qingmei Wang——
Charles Nixon——
Edith Shih—2000
Ling Yang——
Renu Bhatia——
Paul Carter——
Chaohong Hu——
Graeme Jack——
Prof. Shu Kam Mok——
Tak Wai Wong——
David Ng—2024

Revenue by product and region

Fiscal year ended Dec 31, 2025: $548.51M total revenue

By product

  • Represents information pertaining to other collaboration revenue from royalties.$68.42M12.5%
  • Represents information pertaining to commercialization.$45.30M8.3%
  • Represents information pertaining to collaboration research and development.$27.90M5.1%
  • Represents information pertaining to other collaboration revenue from licensing.$12.09M2.2%
  • Represents information pertaining to research and development services.$8.28M1.5%
  • Product [Member]$1.32M0.2%

Similar companies

Companies in the same industry as HUTCHMED (China)

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.